Search
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.
Trandolapril
go.drugbank.com/drugs/DB00519ApprovedInvestigationalIt is metabolized to its biologically active diacid form, trandolaprilat, in the liver. … Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment
Categories: Agents Acting on the Renin-Angiotensin SystemZalifrelimab
go.drugbank.com/drugs/DB15632InvestigationalZalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
Camrelizumab
go.drugbank.com/drugs/DB14776InvestigationalCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. … Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative.
Categories: Antivirals used in combination for the treatment of HIV infectionsTezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.
Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline
Trimethoprim
go.drugbank.com/drugs/DB00440ApprovedInvestigationalVet approved[L11893] Trimethoprim is often used in combination with [sulfamethoxazole] due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of … Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it
Mixtures: Bactrim Roche Inj, SEPTRIN IV 5 ML 10 AMPULNuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational[L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … a productive infection in humans.
Ombitasvir
go.drugbank.com/drugs/DB09296ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Ombitasvir as a first line … First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated